| | |
(n = 12)
| |
|
Male/Female(n)
|
7(70.0%)/3(30.0%)
|
8(80.0%)/4(40.0%)
|
1.000
|
|
Age (years)
|
53 ± 12.9(33~70)
|
40 ± 14.7(25~70)
|
0.050
|
|
Duration (weeks)
|
19 ± 24.8(10~48)
|
34 ± 69.2(0.83~216)
|
0.547
|
|
Extrapulmonary manifestations (n)
| | | |
|
Fever
|
3 (30.0%)
|
7 (58.3%)
|
0.231
|
|
Skin lesions (purpura, gangrene, ulceration)
|
3 (30.0%)
|
3 (25.0%)
|
1.000
|
|
Ear (hearing loss, otitis media)
|
2 (20.0%)
|
4 (33.3%)
|
0.646
|
|
Nasal and sinus involvement
|
5 (50.0%)
|
7 (58.3%)
|
1.000
|
|
Oral ulceration
|
4 (40.0%)
|
1 (8.3%)
|
0.135
|
|
glomerulonephritis
|
6 (60.0%)
|
6 (50.0%)
|
0.691
|
|
Nervous system (facial paralysis, multiple mononeuropathy, etc.)
|
3 (30.0%)
|
1 (8.3%)
|
0.293
|
|
Arthralgia/arthritis
|
4 (40.0%)
|
4 (33.3%)
|
1.000
|
|
Parotid swelling and pain
|
2 (20.0%)
|
0 (0.0%)
|
0.195
|
|
ESR(mm/h)
|
104 ± 26.7
|
82 ± 33.9
|
0.233
|
|
Infection(n)
|
6 (60.0%)
|
3 (25.0%)
|
0.192
|
|
Corticosteroids and Immunosuppressants (n)
| | | |
|
steroid pulse therapy
|
1 (10.0%)
|
4 (33.3%)
|
0.323
|
|
treatment interruption
|
2/4(50.0%)
|
0/8(0.0%)
|
0.091
|
|
Non-response to Pleural drainage (n)
|
5/5 (100%)
|
0/7 (0.0%)
|
0.010
|
|
Surgery(n)
|
2 (20.0%)
|
5 (41.7%)
|
0.381
|
